Results 21 to 30 of about 38,540 (306)

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer

Frontiers in Immunology, 2023
The ErbB family of receptor tyrosine kinases is a primary target for small molecules and antibodies for pancreatic cancer treatment. Nonetheless, the current treatments for this tumor are not optimal due to lack of efficacy, resistance, or toxicity. Here,
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Laurent Gros, Nelly Pirot, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge, Thierry Chardès, Thierry Chardès, Thierry Chardès   +24 more
doaj   +1 more source

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. [PDF]

, 2020
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substantial proportion of patients do not respond to current therapies or have a short duration of response.
Chari, Ajai, Mezzi, Khalid, Scott, Emma, Shah, Nina, Usmani, Saad Z   +4 more
core   +1 more source

Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning

Scientific Reports, 2021
T-cell-redirecting bispecific antibodies have emerged as a new class of therapeutic agents designed to simultaneously bind to T cells via CD3 and to tumor cells via tumor-cell-specific antigens (TSA), inducing T-cell-mediated killing of tumor cells.
Lauric Haber, Kara Olson, Marcus P. Kelly, Alison Crawford, David J. DiLillo, Richard Tavaré, Erica Ullman, Shu Mao, Lauren Canova, Olga Sineshchekova, Jennifer Finney, Arpita Pawashe, Supriya Patel, Ryan McKay, Sahar Rizvi, Ermelinda Damko, Danica Chiu, Kristin Vazzana, Priyanka Ram, Katja Mohrs, Amanda D’Orvilliers, Jenny Xiao, Sosina Makonnen, Carlos Hickey, Cody Arnold, Jason Giurleo, Ya Ping Chen, Courtney Thwaites, Drew Dudgeon, Kevin Bray, Ashique Rafique, Tammy Huang, Frank Delfino, Aynur Hermann, Jessica R. Kirshner, Marc W. Retter, Robert Babb, Douglas MacDonald, Gang Chen, William C. Olson, Gavin Thurston, Samuel Davis, John C. Lin, Eric Smith   +43 more
doaj   +1 more source

Design and characterization of mouse IgG1 and IgG2a bispecific antibodies for use in syngeneic models

mAbs, 2020
The development of antibody therapeutics relies on animal models that accurately recapitulate disease biology. Syngeneic mouse models are increasingly used with new molecules to capture the biology of complex cancers and disease states, and to provide ...
Feng Wang, Jordan C. Tsai, Jonathan H. Davis, Bryant Chau, Jia Dong, Sean M. West, Jason M. Hogan, Matthew L. Wheeler, Christine Bee, Winse Morishige, Thomas Cayton, Donata David-brown, Chengyue Zhang, Alexander Kozhich, Tim Sproul, Gavin Dollinger, Arvind Rajpal, Pavel Strop   +17 more
doaj   +1 more source

Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis

Fluids and Barriers of the CNS, 2022
Background Treatment with amyloid-β (Aβ) targeting antibodies is a promising approach to remove Aβ brain pathology in Alzheimer's disease (AD) and possibly even slow down or stop progression of the disease.
Ulrika Julku, Mengfei Xiong, Elin Wik, Sahar Roshanbin, Dag Sehlin, Stina Syvänen   +5 more
doaj   +1 more source

A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies

mBio, 2020
Broadly neutralizing antibodies (bNAbs) can prevent and control an HIV-1 infection, but their breadth is invariably too limited for use as monotherapy. To address this problem, bi- and trispecific antibody-like constructs have been developed.
Meredith E. Davis-Gardner, Barnett Alfant, Jesse A. Weber, Matthew R. Gardner, Michael Farzan   +4 more
doaj   +1 more source

Selective engagement of FcγRIV by a M2e-specific single domain antibody construct protects against influenza A virus infection [PDF]

, 2019
Lower respiratory tract infections, such as infections caused by influenza A viruses, are a constant threat for public health. Antivirals are indispensable to control disease caused by epidemic as well as pandemic influenza A.
Ballegeer, Marlies, Creytens, Sarah, De Vlieger, Dorien, Hengel, Hartmut, Hoffmann, Katja, Nerinckx, Wim, Remaut, Han, Saelens, Xavier, Schepens, Bert, Van Hoecke, Lien, Van Molle, Inge   +10 more
core   +2 more sources

Nanobody based dual specific CARs [PDF]

, 2018
Recent clinical trials have shown that adoptive chimeric antigen receptor (CAR) T cell therapy is a very potent and possibly curative option in the treatment of B cell leukemias and lymphomas.
Abken, Hinrich, Bonte, Sarah, De Munter, Stijn, Goetgeluk, Glenn, Ingels, Joline, Kerre, Tessa, Pille, Melissa, Vandekerckhove, Bart, Weening, Karin   +8 more
core   +2 more sources

Bispecific antibodies

Drug Discovery Today, 2015
Bispecific antibodies have emerged as molecules with a multitude of ...
Kontermann, Roland E., Brinkmann, Ulrich
openaire   +3 more sources

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. [PDF]

, 2018
Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of ...
Aliberti S, Bareja R, Bonvini E, Bruna R, Brusa D, Chiaretti S, Chichili GR, Cignetti A, Circosta P, Deaglio S, Elemento O, Elia AR, Foà R, Giacomo FD, Gottardi D, Guarini AR, Inghirami G., Johnson S, Kyriakides PW, Landra I, Machiorlatti R, Massaia M, Monteleone E, Moore PA, Todaro M   +24 more
core   +1 more source